National Clinical Trials Network Receives $20 Million Funding Increase from NCI—More Participating Sites

Medical Research Scientist Looking under the Microscope in the Laboratory. Neurologist Solving Puzzles of the Mind and Brain. In the Laboratory with Multiple Screens Showing MRI / CT Brain Scan

The National Clinical Trials Network has received a $20 million funding increase from the National Cancer Institute (NCI) in the latest awards cycle—from $151 million to $171 million.  The network is funded every six years now includes 32 Lead Academic Participating Sites, up from 30 in 2014 reports the Cancer Letter.

What is the NCTM?

The Cancer Letter source article provides more information on the details of the awards and participating sites.

NCI’s National Clinical Trials Network (NCTN)  is a collection of organizations and clinicians that coordinates and supports cancer trials at more than 2,200 sites across the United States, Canada and internationally. NCTN provides the infrastructure for NCI-funded treatment and primary advanced imaging trials to improve the lives of people with cancer.

NCTN clinical trials help to establish new standards of care, set the state for approval of new therapies for FDA, test new treatment approaches and validate new biomarkers.  The network has launched a number of clinical trials, many ongoing, which can be accessed here:

Network Groups and their Support Components

The NCTM organizational structure is ideal for screening large numbers of patients to find those whose tumors exhibit the molecular features that give them the best chance of responding to new, targeted treatments. A menu of important trials is widely available throughout the country, in large cities and small communities alike. NCTN offers a shared infrastructure and access to knowledge to best approaches available for many common and, increasingly, even rare cancers.

Oversight of the NCTN—its organizational structure, funding, and long-term strategic direction—is under the purview of the Clinical Trials Translational Research Advisory Committee (CTAC). This federal advisory committee is composed of clinical trials experts, industry representatives, and patient advocates from across the nation and provides recommendations to the NCI director.  TrialSite News provides a link to the “Roster” here which is a list of members and the Chair and Director Patrick, J. Loehrer, Dr. M.D. 2020 Director Indiana University Melvin and Bren Simon Cancer Center, Associate Dean for Cancer Research Indiana University School of Medicine.